Aetna Better Health®
2000 Market Street, Suite 850
Philadelphia, PA 19103

AETNA BETTER HEALTH®

Clinical Policy Bulletin:
Thoracoscopic Sympathectomy

Number: 0310

Policy

I. Aetna considers thoracoscopic sympathectomy medically necessary for any of the following conditions:

A. Causalgia; or
B. Catecholaminergic polymorphic ventricular tachycardia (CPVT), in persons who remain symptomatic despite maximal medical therapy; or
C. Long QT syndrome, in persons who have failed medical therapy and have frequent shocks with an ICD despite medications; or
D. Raynaud’s disease; or
E. Shoulder-hand syndrome; or
F. Some types of visceral pain (e.g., chronic pancreatic pain and cancer-derived visceral abdominal pain); or
G. Vascular occlusive disease; or
H. Intractable, disabling primary hyperhidrosis (excessive sweating) when all of the following are met (see also CPB 0504 - Hyperhidrosis (Hyperhydrosis))

- Iontophoresis or electrophoresis, (e.g., Drionic® device) is ineffective (see CPB 0229 - Iontophoresis) (a trial of botulinum toxin can be substituted for iontophoresis in persons with predominantly axillary hyperhidrosis -- see CPB 0113 - Botulinum Toxin); and
- Significant disruption of professional and/or social life has occurred because of excessive sweating; and
- Topical aluminum chloride or other extra-strength antiperspirants are ineffective or result in a severe rash; and
- Unresponsive or unable to tolerate pharmacotherapy prescribed for excessive sweating (e.g., anti-cholinergics, beta-blockers, benzodiazepines) if sweating is episodic.

http://qawww.aetna.com/cpb/medical/data/300_399/0310_draft.html
II. Aetna considers thoracoscopic sympathectomy cosmetic for excessive spontaneous facial blushing. Facial blushing (flushing) is considered a cosmetic indication as it does not result in functional impairment.

III. Aetna considers thoracoscopic sympathectomy experimental and investigational for all other indications because its effectiveness for indications other than the ones listed above has not been established.

IV. Aetna considers left thoracoscopic sympathectomy experimental and investigational for cardiac denervation in persons with ventricular arrhythmias and heart failure because the effectiveness of this approach for these indications has not been established.

See also CPB 0031 - Cosmetic Surgery.

Background

A report by the Finnish Office of Health Technology Assessment systematically evaluated the literature on the safety and effectiveness of thoracoscopic sympathectomy for treatment of sweating and for treatment of social phobia (Malmivaara et al, 2005). Thoracoscopic sympathectomy aims to reduce excessive sweating of the face and hands and facial flushing by interrupting stimulation of sweat glands by the sympathetic nervous system. The treatment is performed as an endoscopic procedure, where the upper thoracic chain of the sympathetic nerve trunk is transected or clamped.

The authors stated that it is difficult to conduct even a qualitative synthesis of studies of thoracoscopic sympathectomy, due to poor reporting of patient characteristics and variation among studies in the reporting of outcomes (Malmivaara et al, 2005). In addition, the authors found most of the studies to be of poor methodologic quality. The authors stated, however, that available literature suggests that thoracoscopic sympathectomy reduces excessive sweating of the palms and facial flushing. Patient satisfaction was reported as good or moderately good. The authors identified only 1 study that followed subjects for more than 2 years.

The reported rates of acute post-operative complications following endoscopic thoracic sympathectomy varied widely among studies studies (Malmivaara et al, 2005). Acute post-operative complications, some severe, occurred in as many as 10 % of subjects. The most commonly reported chronic complication was compensatory sweating below the breast level, often with substantial resultant disability. Other chronic complications included dryness of the face or palms and gustatory sweating. The authors noted that, due to wide variation in the reporting of complications, it is probable that these complications have been under-reported in most series.

The authors concluded that “due to lack of controlled trials there is no reliable evidence for the effectiveness of endoscopic thoracic sympathectomy for excessive sweating in the face and hands or for flushing of the face” (Malmivaara et al, 2005). The authors also found no reliable evidence of the effectiveness
of endoscopic thoracoscopic sympathectomy for social phobia. The authors concluded that endoscopic thoracic sympathectomy is associated with significant immediate and long-term adverse effects.

A follow-up article to the FinOHTA assessment (Malmivaara et al, 2007) re-affirmed these earlier findings, concluding that: “The evidence for the effectiveness of ETS [endoscopic thoracic sympathectomy] is weak. The intervention is associated with severe immediate complications in some patients and persistent adverse effects for many.” The methodological quality and the reporting of clinically relevant characteristics were poor. The quality scores of the included studies ranged from 0 to 8; only 3 studies scored 6 or more. The authors stated that blushing and excessive sweating decreased after ETS in all studies, but no further details were reported. Complications following ETS included pneumothorax and/or haemothorax and Horner’s syndrome in some patients in almost all studies. Compensatory excessive sweating was observed in 50 % or more of patients in 13 of the 15 studies, and was considered to cause significant disability in 3 to 15 % of those who experienced it.

A review by the Royal Australasian College of Surgeons (Watt et al, 2009) concluded that “[a] lack of high quality randomised trial evidence on ETS means that it is difficult to make a judgment on the safety and effectiveness of this technique”, and that “[t]here is potentially a number of safety issues associated with this procedure.”

Patients with palmar hyperhidrosis who fail topical therapies and iontophoresis, and who do not tolerate or get relief from botulinum toxin, can be treated effectively with endoscopic thoracic sympathectomy (Smith, 2008). Side effects, especially compensatory hyperhidrosis in other parts of the body, may reduce long-term patient satisfaction with this procedure. Endoscopic thoracic sympathectomy can also be used for axillary hyperhidrosis, but the relapse rate is high.

Hofferberth et al (2014) reported the outcomes of a single-institution experience using video-assisted thoracoscopic left cardiac sympathetic denervation as an adjunctive therapeutic technique in pediatric and young adult patients with life-threatening ventricular arrhythmias. These investigators conducted a retrospective clinical review of all patients who underwent left cardiac sympathetic denervation by means of video-assisted thoracoscopic surgery at the authors’ institution. From August 2000 to December 2011, a total of 24 patients (13 with long QT syndrome, 9 with catecholaminergic polymorphic ventricular tachycardia, and 2 with idiopathic ventricular tachycardia) were identified from the cardiology database and surgical records. There were no intra-operative complications. The median post-operative length of stay was 2 days (range of 1 to 32 days). There were no major peri-operative complications. Longer-term follow-up was available in 22 of 24 patients at a median follow-up of 28 months (range of 4 to 131 months). Sixteen (73 %) of the 22 patients experienced a marked reduction in their arrhythmia burden, with 12 (55 %) becoming completely arrhythmia-free after sympathectomy. Six (27 %) of the patients were non-responsive to treatment; each had persistent symptoms at follow-up. The authors concluded that video-assisted thoracoscopic left cardiac sympathetic denervation can be safely and effectively performed in most patients with life-threatening ventricular arrhythmias. They stated that this minimally invasive procedure is a promising adjunctive
therapeutic option that achieves a beneficial response in most symptomatic patients. These preliminary findings need to be validated by well-designed studies.

De Ferrari and Schwartz (2014) stated that heart failure (HF) is characterized by an autonomic imbalance with withdrawal of vagal activity and increased sympathetic activity. Novel non-pharmacological approaches to HF aimed at increasing vagal activity are being proposed. Left cardiac sympathetic denervation (LCSD) has been shown to modify favorably the outcome of several disorders characterized by life-threatening arrhythmias triggered by increased sympathetic activity. These investigators discussed the rationale and the limited experimental and clinical experience suggesting a potential role for LCSD in the treatment of patients with advanced HF. Possible future clinical applications of LCSD may include HF patients who are intolerant to beta-adrenergic blockade, HF patients who have frequent implantable cardioverter-defibrillator shocks, and HF patients in countries where the likelihood of receiving a device is limited, but the capability to perform a one in a lifetime procedure is present.

An UpToDate review on “Management of refractory heart failure” (Colucci, 2015) does not mention thoracoscopic sympathectomy as a therapeutic option.

Costello et al (2015) stated that congenital ion channel disorders, including congenital long QT syndrome (LQTS), cause significant morbidity in pediatric patients. When medication therapy does not control symptoms or arrhythmias, more invasive treatment strategies may be necessary. These researchers examined their institution’s clinical experience with surgical cardiac denervation therapy for management of these arrhythmogenic disorders in children. An institutional review board-approved retrospective review identified 10 pediatric patients with congenital ion channelopathies who underwent surgical cardiac denervation therapy at a single institution between May 2011 and April 2014; 8 patients had a diagnosis of congenital LQTS, 2 patients were diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT). All patients underwent sympathectomy and partial stellate ganglionectomy via video-assisted thoracoscopic surgery (VATS). Six of the 10 patients had documented ventricular arrhythmias pre-operatively, and 70 % of the patients had pre-operative syncpe. The corrected QT interval decreased in 75 % of patients with LQTS following sympathectomy. Post-operative arrhythmogenic symptoms were absent in 88 % of congenital LQTS patients, but both patients with CPVT continued to have symptoms throughout the duration of follow-up. All patients were alive after a median follow-up period of 10 months. The authors concluded that surgical cardiac denervation therapy via VATS is a useful treatment strategy for congenital LQTS patients who failed medical management, and its potential benefit in the management of CPVT is unclear. They stated that a prospective comparison of the effectiveness of surgical cardiac denervation therapy and implantable cardioverter-defibrillator use in congenital ion channelopathies is timely and crucial.
CPT codes covered if selection criteria are met:
32664  Thoracoscopy, surgical; with thoracic sympathectomy

Other CPT codes related to the CPB:
64650  Chemodenervation of eccrine glands; both axillae
64804  Sympathectomy, cervicothoracic
97033  Application of a modality to one or more areas; iontophoresis, each 15 minutes

Other HCPCS codes related to the CPB: J0585
    Botulinum toxin type A, per unit
J0587  Botulinum toxin type B, per 100 units

ICD-9 codes covered if selection criteria are met:
354.4  Causalgia of upper limb
355.71 Causalgia of lower limb
443.0  Raynaud's syndrome
705.21 Primary focal hyperhidrosis [intractable, disabling - see criteria]
705.22 Secondary focal hyperhidrosis [intractable, disabling - see criteria]

ICD-9 codes not covered for indications listed in the CPB:
427.1  Paroxysmal ventricular tachycardia
427.2  Unspecified paroxysmal tachycardia
427.41 Ventricular fibrillation
427.42 Ventricular flutter
782.62 Flushing

Other ICD-9 codes related to the CPB:
337.9  Unspecified disorder of the autonomic nervous system [shoulder-hand syndrome]
459.9  Unspecified circulatory system disorder [vascular occlusive disease]
780.8  Generalized hyperhidrosis

The above policy is based on the following references:


